Clearside Biomedical Announces Multiple Poster Presentations at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting
10 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 10, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Report First Quarter 2021 Financial Results and Provide Corporate Update on Monday, May 17, 2021
04 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
03 mai 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., May 03, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
10 mars 2021 16h05 HE
|
Clearside Biomedical, Inc.
- OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - - Initial Safety Data from OASIS Trial Expected Mid-2021 - - Four Ongoing Internal & Partner Clinical Trials Using...
Clearside Biomedical to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update on Wednesday, March 10, 2021
24 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021
23 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program
16 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
08 févr. 2021 07h05 HE
|
Clearside Biomedical, Inc.
- Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders - - CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation,...
Clearside Biomedical Announces Pricing of $12 Million Registered Direct Offering
06 janv. 2021 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Clearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology
16 nov. 2020 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...